Skip to content
Peptigraph home

Orforglipron Phase 2 trial (NCT05048719)

A Phase 2 Study of Once-Daily LY3502970 Compared With Placebo and Once-Weekly Dulaglutide in Participants With Type 2 Diabetes Mellitus

Registry record checked

At a glance

Phase
Phase 2
Status
Completed
Enrolment
383
actual
Start
15 Sep 2021 (actual)
Primary completion
30 Sep 2022 (actual)
Sponsor
Eli Lilly and Company
Design

Arms and doses

NCT05048719 study arms
ArmTypeInterventionsDescription
3 milligrams (mg) LY3502970ExperimentalDrug: LY3502970Participants received maintenance dose of 3 mg with dose escalation starting from 2 mg LY3502970 administered orally once daily (QD).
12 mg LY3502970ExperimentalDrug: LY3502970Participants received maintenance dose 12 mg with dose escalation starting from 2 mg, 6 mg and then 12 mg LY3502970 administered orally QD.
24 mg LY3502970ExperimentalDrug: LY3502970Participants received maintenance dose 24 mg with dose escalation starting from 3 mg, 6 mg, 8 mg,12 mg and then 24 mg LY3502970 administered orally QD.
36 mg LY3502970 - 1ExperimentalDrug: LY3502970Participants received maintenance dose 36 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 8 mg, 12 mg, 24 mg and then 36 mg LY3502970 administered orally QD.
36 mg LY3502970 - 2ExperimentalDrug: LY3502970Participants received maintenance dose 36 mg with dose escalation starting from 3 mg, 6 mg,12 mg, 24 mg and then 36 mg LY3502970 administered orally QD.
45 mg LY3502970 - 1ExperimentalDrug: LY3502970Participants received maintenance dose 45 mg with dose escalation starting from 3 mg, 6 mg, 8 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally QD.
45 mg LY3502970 - 2ExperimentalDrug: LY3502970Participants received maintenance dose 45 mg with dose escalation starting from 2 mg, 3 mg, 6 mg, 12 mg, 24 mg, 36 mg and then 45 mg LY3502970 administered orally QD.
1.5 mg DulaglutideActive comparatorDrug: DulaglutideParticipants received 1.5 mg Dulaglutide administered subcutaneously (SC) once weekly (QW).
PlaceboPlacebo comparatorDrug: PlaceboParticipants received matching placebo.
Endpoints

Primary endpoint

NCT05048719 primary outcomes
MeasureTime frame
Change From Baseline in HbA1c in LY3502970 as Compared to PlaceboBaseline, Week 26
Endpoints

Key secondary endpoints

The first secondary outcomes listed on the registry record.

NCT05048719 secondary outcomes
MeasureTime frame
Change From Baseline in HbA1c in LY3502970 as Compared to DulaglutideBaseline, Week 26
Percentage of Participants With HbA1c ≤ 6.5%Week 26
Percentage of Participants With HbA1c <7.0%Week 26
Change From Baseline in Fasting Serum GlucoseBaseline, Week 26
Change From Baseline in Body WeightBaseline, Week 26
Pharmacokinetics (PK): Steady State Area Under the Concentration Curve (AUC) of LY3502970Pre-dose (Week (wk) 0, wk 8, wk 12, and wk 26); Post-dose (wk 4, wk 8, wk 16, wk 20, and end of treatment).
Eligibility

Who could enrol

Sex
All
Minimum age
18 Years
Maximum age
75 Years
Results

Results

Results are posted on the registry. Open the ClinicalTrials.gov record for NCT05048719.

The oral orforglipron type 2 diabetes dose-response study

Adults with type 2 diabetes were randomised 5:5:5:5:5:3:3:3:3 to placebo, dulaglutide 1.5 mg weekly, or daily orforglipron at 3, 12, 24, 36 or 45 mg, with two escalation regimens tested for 36 mg and 45 mg.[2]

At week 26, HbA1c fell by up to 2.10% with orforglipron against 0.43% with placebo and 1.10% with dulaglutide.[2]

Bodyweight fell by up to 10.1 kg with orforglipron, versus 2.2 kg with placebo and 3.9 kg with dulaglutide.[2]

Treatment-emergent adverse events occurred in 61.8% to 88.9% of orforglipron recipients, with gastrointestinal events at 44.1% to 70.4%.[2]

Sources

  1. 1A Phase 2 Study of Once-Daily LY3502970 Compared With Placebo and Once-Weekly Dulaglutide in Participants With Type 2 Diabetes MellitusClinicalTrials.gov (U.S. National Library of Medicine) · registry recordclinicaltrials.govAccessed 2 Oct 2026
  2. 2Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study.Lancet (London, England) · 2023PMID 37369232Accessed 2 Oct 2026

Found an error? Report a correction.